CRVS — Corvus Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $71.11m
- $43.96m
- 13
- 26
- 68
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 78 | 44.3 | 69.5 | 42.3 | 27.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.329 | 0.086 | 0.539 | 0.633 | 0.063 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 79.3 | 45.3 | 71.3 | 43.7 | 28 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.79 | 2.55 | 3.64 | 2.57 | 1.39 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 83.6 | 85.5 | 109 | 68.2 | 45.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 10.2 | 12.1 | 9.69 | 10.8 | 6.87 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.5 | 13.4 | 12.3 | 12.1 | 6.87 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 71.1 | 72.1 | 97.2 | 56.1 | 38.7 |
Total Liabilities & Shareholders' Equity | 83.6 | 85.5 | 109 | 68.2 | 45.6 |
Total Common Shares Outstanding |